AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 303 min read$NRXP

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

NRx Pharmaceuticals (NRXP) received FDA approval for its preservative-free ketamine injection ahead of the November 10 goal date. The company aims to address drug shortages and reshoring manufacturing. NRXP will host a conference call on October 30, 2026, to discuss the approval. The company has other drug candidates in development, including NRX-100 and NRX-101, with designations for treating depression and suicidality.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$NRXPBullishHigh
01

Why it matters

The approval removes a regulatory hurdle, potentially unlocking US manufacturing and expanding market opportunities for NRx, which could drive a share price rally.

02

Market read

NRx's FDA approval could trigger a stock rally and influence the broader CNS drug market by demonstrating a path to domestic manufacturing of sterile injectables.

03

What to watch

Pricing, insurance coverage, and need for further clinical data could temper the stock impact.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

NRx Pharmaceuticals announced FDA approval of its preservative‑free ketamine injection, a first for the drug class, and scheduled a conference call to discuss the milestone. The company also highlighted a DARPA contract for a related oral drug and fast‑track designations for its pipeline.

Company-level read

Ticker impact

$NRXPBullishHigh confidence
Context

NRx Pharmaceuticals received FDA approval for preservative-free ketamine, a new injectable formulation.

Expected impact

likely upside as market prices in the approval and potential sales

Evidence & confidence

Approval is a material regulatory milestone for a clinical-stage biotech, expected to boost share price.

Market effects

Sector

May lift sentiment for ketamine and CNS drug sector and encourage US manufacturing of sterile injectables.

Regional

Provides a domestic source in the US, reducing reliance on offshore injectable supplies.

Global

Sets a precedent for preservative‑free formulations that could influence global drug development.

Counterpoint

What could challenge this read

Approval may not translate to sales if reimbursement, adoption, or competition limit market penetration.

Key entities

  • company
    NRx Pharmaceuticals

    Clinical‑stage biopharma developing NMDA‑receptor therapeutics.

  • regulator
    U.S. Food and Drug Administration

    Approved the preservative‑free ketamine formulation.

  • government_agency
    Defense Advanced Research Projects Agency

    Awarded an $11.25 million contract to NRx for a phase‑3 trial.

Read at source← All news

StoryFDA approves NRx’s preservative‑free ketamine injection ahead of target date

Also covered by

5 outlets

Related articles

OCT 30
$NRXPMedAI 8/10

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection

NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its preservative-free ketamine injection, addressing a national drug shortage. The company's manufacturing technology allows for faster production. NRx plans to target hospitals, wholesalers, and clinics, with initial focus on converting top-tier hospital customers. The company expects to introduce additional ketamine products in 2027 and is developing other CNS treatments, including NRX-101 for bipolar depression.

finance.yahoo.com7 min
OCT 30
$NRXPHighAI 9/10

Why is NRX Pharmaceuticals stock surging today?

NRX Pharmaceuticals' stock rose 14.3% in pre-market trading after FDA approval of its Preservative-Free Ketamine, ahead of the expected November 10 date. The company completed pre-launch manufacturing requirements and received an $11.25 million DARPA contract for a Phase 3 trial of NRX-101. CEO Jonathan Javitt expressed excitement about the market launch.

investing.com2 min
OCT 30
$NRXPHighAI 8/10

NRx Pharmaceuticals Secures FDA Nod For Preservative-Free Ketamine Ahead Of Target Date; Stock Up

NRx Pharmaceuticals (NRXP) received FDA approval for its preservative-free ketamine injection, ahead of the November 10 target date. The company claims the formulation addresses concerns about potential toxicity from the preservative BZT. NRx has supply ready for U.S. distribution and is manufacturing the product with Nephron Pharmaceuticals. The stock was up 16.60% in pre-market trading.

rttnews.com1 min
OCT 30
$NRXPHighAI 9/10

The FDA approved ketamine without a preservative found in every currently available ketamine injection.

NRx Pharmaceuticals (NRXP) announced FDA approval for its preservative-free ketamine injection, ahead of the November 10 goal date. The product lacks benzethonium chloride, a toxic preservative in current ketamine injections. NRx aims to address the ketamine shortage and reshored manufacturing to the U.S. with Nephron Pharmaceuticals. The company will host a conference call on October 30 to discuss the approval.

stocktitan.net2 min